A5029389270- Botulinum Toxin and Related Neurological Disorders
- Hereditary Neurological Disorders
- Nutrition and Health in Aging
- Hepatitis B Virus Studies
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Hepatitis C virus research
- Parkinson's Disease Mechanisms and Treatments
- Stroke Rehabilitation and Recovery
- Health and Wellbeing Research
- Health disparities and outcomes
- Shoulder Injury and Treatment
- Ergonomics and Musculoskeletal Disorders
- Dysphagia Assessment and Management
- Body Composition Measurement Techniques
- Herpesvirus Infections and Treatments
- Musicians’ Health and Performance
- Smoking Behavior and Cessation
- Pharmacy and Medical Practices
- Liver Disease Diagnosis and Treatment
- Cardiovascular Syncope and Autonomic Disorders
- Diabetes, Cardiovascular Risks, and Lipoproteins
- HIV/AIDS drug development and treatment
- Peripheral Nerve Disorders
- Air Quality and Health Impacts
- Cerebral Palsy and Movement Disorders
Nagasaki University
2014-2024
GlaxoSmithKline (Japan)
2010-2017
Showa University Hospital
2010
GlaxoSmithKline (United Kingdom)
2008-2010
Jikei University School of Medicine
2010
Kanazawa University
2001
Lower limb spasticity in post-stroke patients can impair ambulation and reduces activities of daily living (ADL) performance patients. Botulinum toxin type A (BoNTA) has been shown effective for upper spasticity. This study assesses the treatment lower a large placebo-controlled clinical trial. In this multicenter, randomized, double-blind, parallel-group, study, we evaluate efficacy safety one-time injections botulinum Japanese with One hundred twenty were randomized to single BoNTA 300 U...
Objective:To evaluate the efficacy and safety of one-time injections botulinum toxin type A (BoNTA) in Japanese patients with post-stroke upper limb spasticity.Research design methods:In a multicentre, randomised, double-blind, parallel-group, placebo-controlled study, 109 spasticity were randomised to receive single treatment lower-dose (120–150 U) or higher-dose (200–240 BoNTA placebo into muscles.Clinical trial registration:NCT00460564Main outcome measures:The tone wrist flexor was...
The study aimed to evaluate the efficacy and safety of tenofovir disoproxil fumarate (TDF) entecavir hydrate (ETV) in nucleos(t)ide analog (NA)-naïve Japanese chronic hepatitis B (CHB) patients.This multicenter, randomized, double-blinded assessing TDF 300 mg ETV 0.5 NA-naïve CHB subjects was carried out from November 2011 2014, funded by GlaxoSmithKline. were assigned arm or a 2:1 ratio. primary endpoint non-inferiority at week 24.A total 166 (TDF arm, 110; 56) enrolled. change (mean ± SE)...
To examine the relationship between living location and outcomes of physical activity level psychological functioning in older women. The specific aim was to understand association a sloped versus non-sloped environment these outcomes.
Acquisition of nucleos(t)ide analog (NA) inhibitor resistance is critical in successful chronic hepatitis B treatment. As the pattern tenofovir disoproxil fumarate (TDF) mutations differs from that other antiviral drugs, we sought to clarify salvaging potential TDF patients with virus (HBV) infection who are poor responders or resistant NAs.A prospective, multicenter, single-arm, open-label study was carried out December 2011 October 2014. Poor defined as subjects serum HBV-DNA levels >4...
【目的】脳卒中後の下肢痙縮患者を対象にA 型ボツリヌス毒素製剤(botulinum toxin type A:BTXA)単回投与時の有効性をプラセボを対照として検証し,反復投与した際の有効性および安全性を評価した.【方法】下肢痙縮患者120 例にBTXA300 単位またはプラセボを対象筋に1 回筋注し,投与12 週以降は再投与基準を満たした被験者にBTXA300 単位を最大3 回反復投与し,48 週まで観察を行った.【結果】足関節のModified Ashworth Scale(MAS)の投与前からの変化量に基づく曲線下面積の平均値の差は,BTXA群とプラセボ群間で-3.428であり,BTXA群で有意な減少が認められた(p=0.006,t検定).反復投与によりMASは更なる改善を示した.副作用発現頻度はBTXA群,プラセボ群間で著明な差は認められず,反復投与において副作用発現率の増加は認められなかった.【結論】BTXAは初回投与から下肢痙縮を改善し,長期的に有効で安全な治療法に成り得ると考えられた.
【目的】脳卒中後の上肢痙縮患者を対象にA型ボツリヌス毒素製剤 (botulinum toxin type A:BTXA) 単回投与時の有効性をプラセボを対照として検証し,反復投与した際の有効性および安全性を評価した.【方法】上肢痙縮患者109 例にBTXA低用量(120~150 単位),高用量(200~240 単位)またはプラセボを手関節,手指関節,母指関節 (母指に痙縮が認められた場合) の対象筋に1 回筋注し,投与12 週以降は再投与基準を満たした被験者にBTXA 200~240 単位を最大3 回反復投与し48 週まで観察を行った.【結果】手関節のModified Ashworth Scale...
〔目的〕健常高齢者の身体活動量を歩数のみで評価できるかを検討すること．〔対象と方法〕対象は102名の健常高齢者とした．1日の身体活動量（歩数と身体活動関連エネルギー消費量 “PAEE”）は単軸加速度計を用いて評価した．加えて，身体活動に関連すると考えられる因子（BMI，大腿四頭筋筋力，握力，呼吸機能，うつ症状，地域別環境，装着率）を評価した．〔結果〕歩数とPAEEには高い相関が認められた．さらに，重回帰分析により，年齢，握力，大腿四頭筋筋力，装着率は歩数とPAEEに影響を与える共通の因子であることが明らかとなった．〔結語〕歩数がPAEEに対して充分な評価指標となり，健常高齢者の身体活動量は歩数のみで評価できることが示唆された．
Background: The impact of airway obstruction nonsmoking women caused by their husband’s smoking is unclear, despite the association between environmental tobacco smoke (ETS) exposure at home and obstructive pulmonary diseases among women. aim this study was to provide evidence that ETS from husband has a more significant influence on than other housemates. Participants methods: Nonsmoking aged 40 years or older were recruited health checkup during May 2015–December 2016, Japan. They answered...
To attain good medication compliance is the major premise in well-controlled clinical trials. We conducted a questionnaire survey on 40 investigators, 25 sponsors and 20 trial subjects during Oct.-Dec. 1998 to investigate correlation among actual circumstances of evaluation by investigators sponsors, determine effective measures improve compliance. Whereas almost all evaluated or expected over 70% compliance, answered 90%.The (95%) (96%) thought actuality that primary means maintain was for...
〔目的〕整形外科術後に理学療法を実施した運動器疾患患者における閉塞性換気障害を合併する割合とその特徴を明らかにすること．〔対象と方法〕当院にて術後理学療法を実施した40歳以上の男性肩腱板損傷患者を対象とした．方法は患者背景，術前呼吸機能検査，喫煙状況について後方視的に調査し，閉塞性換気障害を合併する割合とその特徴について検討した．〔結果〕解析対象者101名のうち，閉塞性換気障害を合併した者は6名（5.9％）であり，6名中3名が70歳以上の現喫煙者（ブリンクマン指数：1000以上）であった．〔結語〕喫煙歴を有する高齢の運動器疾患患者のなかには，閉塞性換気障害を有する可能性があることを理学療法士は認識する必要がある．